OCI Acquires 11% Stake in Bukwang Pharm for 146.1 Billion KRW, Becomes Largest Shareholder
[Asia Economy Reporter Kwon Jae-hee] OCI announced on the 22nd that it will acquire 7,730,334 shares held by Chairman Kim Dong-yeon, the largest shareholder of Bukwang Pharm, and 9 other related parties for 146.1 billion KRW.
This corresponds to 6.12% of OCI's equity capital.
With this acquisition, OCI's shares in Bukwang Pharm will increase to 7,747,934 shares, raising its stake to 10.90%.
OCI stated, "The acquisition was made to expand our entry into the bio business."
Hot Picks Today
"Koreans Spend 1 Million Won Each and Come Back"... 'They Said They Were Going for Value for Money,' but Open Their Wallets Wide in Japan- "Wow, Have Middle-Aged Men Had This All to Themselves?"... Women in Their 20s and 30s Find Comfort in a Standing Drink
- They Earn “430 Million Won a Year” Yet Receive Government Aid... AI Hub Declares Emergency Over “8.8 Million Won Monthly Rent”
- "Naked Again?" Controversial Actress Crosses a Line... Slammed for Sexualizing 'Child Characters'
- "They Get a Good Night's Sleep and Earn Twice My Salary... Honestly, I'm So Jealous I Could Die": Civil Servant's Post Targeting Firefighters Sparks Outrage
The scheduled date for the stock acquisition is March 8.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
